Ablynx - BE0003877942 (Page 32 sur 32)

beau pipe line,>  conserver ca fait partie du jeu quand on investi la dedans.
tout dépend du poids qu'elle représente chez toi et de ce que tu ferais avec cet argent,

Salut tout le monde,

tout çà ne parait pas si mal, or ce matin la baisse continue. En acheter aux cours actuels ?
@Benjamin : à ta place je garderais. 

Nov 23 (Reuters) - Ablynx NV  ABLX.BR :
    * 9-month revenue 68.9 million euros ($73.22 million) versus 53.6 million euros year ago
    * 9-month operating loss of 13.6 million euros versus loss of 13.3 million euros year ago
    * 9-month net profit of 10.9 million euros versus loss 21.7 million euros year ago
    * Cash position at September 30 of 263.6 million euros compared to 262.2 euros at 30
September 2015
    * 2016 outlook and financial guidance confirmed
    * Reiterates its net cash burn guidance for full year 2016 of 65-75 million euros, not
including net proceeds from private placement of new shares announced on June 1, 2016
    * Has started process of identifying a new partner for vobarilizumab in RA
    * Before year-end, expects to start a phase IIb dose-ranging efficacy study with inhaled
ALX-0171
    * Recruitment of 300 patients in SLE Phase II study ahead of schedule; results anticipated
in H1 2018
    * On track to file for conditional approval of caplacizumab in Europe in early 2017

Voici l'avis de Bolero (KBC) ce matin. Leur conseil est à l'achat mais ils ont ramené l'obj de 18 à 15,50. Ca vaut ce que ça vaut mais c'est qd mm p-ê une indication par rapport à ce qui en a été dit par le passé.
Our View/Conclusion:
Capla’s second indication was communicated but first clinical
development/results are logically still far off. We therefore do not yet take this
indication into account in the market potential of the asset. All programmes in
general are nicely on track with results coming out at a timing that was
previously reported. For the time being, we leave the voba potential in RA out
of the equation due to the uncertainty in timing of finding a new partner. This
could well be in 2H17 or around the SLE data in 1H18. We leave it as
upwards potential for the time being. Our sum-of-the-parts regarding voba
amounted to € 3/sh which is cut by € 2.5/sh, to ~€ 0.5/sh reflecting the lupus
development value. The target price lowers from € 18/sh to € 15.5/sh
warranting a Buy rating following the current trading levels of the stock and
backs our long-term view on the company (Capla, RSV, upside of voba,…).
Note that 2017 will contain limited stock triggering news flow based on the
current view on the developments.
News:
Finance: 9M16 revenues came in € 68.9m, up 29% 9M15. Operating loss
widened a little bit to € 13.7m vs € 13.3m 9M15. Net profit occurred due to
accounting treatment of outstanding convertible bond, i.e. € 10.9m. In
general, a positive net cash inflow occurred of € 27.4m during 9M16 due to
the capital raise of € 71.4m earlier this year. Cash position at € 263.6m
compared to € 262.2 at 9M15. Financial guidance of net cash burn of € 65-
75m reiterated, excluding the private placement net proceeds.
Business update: Caplacuzimab – HERCULES phase III results expected in
2H17 which would give the possibility to do a BLA submission (FDA) mid-
2018. Initial patient population increased to 132 from 92 and program is
ahead of schedule. 3y follow-up study also initiated (results expected 2H20).
On track for EU conditional approval filing early 2017. Capla will also start
its clinical development in Japan around mid-2017 and will be studied in
Reperfusion Injury (stroke) of which the preclinical work will start 1H17 with
first clinical development expected in 2H18.
Anti-RSV – Phase IIb dose-ranging efficacy study in 180 hospitalized infants
with RSV infections on track to start by YE16 with topline results expected
2H18. Clinical development will also be initiated in haematopoietic stem cell
transplant patients by YE17 who are immunocompromised for their transplant
and thus susceptible to RSV infection. Mid-2018, clinical development will
also start in Japan.
Voba – Partner search for further RA development ongoing. End-of-Phase II
meetings with EMA and FDA planned for 1H17. SLE phase II ahead of
schedule, results anticipated in 1H18.
Partnerships: Merck & Co (Ion channel) extended for the 2nd time (€ 1m) and
3 partnered nanobody programmes entered phase I (>€ 16m, mostly from
Boehringer).
More than 15 preclinical programmes up and running.

ABLYNX OBTIENT PREMIER MILESTONE DANS LE CADRE DE COLLABORATION AVEC NOVO NORDISK

AND, Belgique, le 30 Novembre 2016 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] a annoncé aujourd'hui qu'elle a franchi une étape de découverte initiale avec un Nanobodies multi-spécifique construire dans le cadre de sa collaboration avec Novo Nordisk, déclenchant un paiement EUR1 millions d'étape à Ablynx.

Selon les termes de l'accord avec Novo Nordisk, signé le 25 Novembre 2015, Ablynx a reçu un droit de licence initial de 5 millions d'euros et recevra jusqu'à millions de EUR4 dans le financement de la recherche pendant la durée de la recherche initiale de trois ans de la collaboration. En outre, Ablynx est admissible à recevoir le développement potentiel, des paiements d'étapes réglementaires et commerciales pouvant atteindre EUR182 millions, plus des redevances progressives sur les ventes nettes annuelles de tous les produits issus de la collaboration. Novo Nordisk est responsable pour le développement, la fabrication et la commercialisation de tous les produits résultant de cet accord.

Dr Edwin Moses, PDG de Ablynx, a commenté: "Notre plate - forme technologique de Nanobodies exclusive est idéale pour développer des candidats Nanobodies multi-spécifiques qui répondent à des cibles multiples dans une molécule de médicament unique La réalisation de notre premier jalon juste un an après nous sommes entrés dans la. collaboration avec Novo Nordisk est une reconnaissance de la puissance de notre plate - forme pour générer rapidement des nouvelles, des candidats médicaments puissants contre des cibles de maladies qui sont difficiles à traiter avec d' autres technologies. Nous sommes impatients de faire avancer le programme et le Nanobodies potentiellement progresser vers des études cliniques en 2018. "

Bingo Manu !! Je vais réduire ma position avec une plus-value d'environ 8%. Merci pour les échanges précédents